

# Clinical Policy: Transcatheter Closure of Patent Foramen Ovale

Reference Number: CP.MP.151

Last Review Date: 11/20

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

## Description

Patent foramen ovale (PFO) is a congenital cardiac lesion which is generally asymptomatic and affects up to a quarter of the population. PFO can present with an array of significant clinical complications, including cryptogenic stroke. This policy describes the medical necessity requirements for the percutaneous transcatheter closure of a patent foramen ovale with the Amplatzer™ PFO Occluder or Gore® Cardioform Septal Occluder.

## Policy/Criteria

- I. It is the policy of health plans affiliated with Centene Corporation® that the percutaneous transcatheter closure of PFO with an FDA-approved device (Amplatzer PFO Occluder or Gore Cardioform) is **medically necessary** to reduce the risk of recurrent ischemic stroke when meeting the following indications:
  - A. Age  $\geq 18$  and  $\leq 60$ ;
  - B. Both a neurologist and a cardiologist confirm all of the following:
    1. PFO with a right-to-left interatrial shunt detected by bubble study;
    2. Cryptogenic stroke caused by a presumed paradoxical embolism;
    3. Absence of other risk factors of ischemic stroke, including but not limited to, any of the following:
      - a. Atherosclerosis;
      - b. Small vessel occlusion;
      - c. Hypercoagulable state;
      - d. Atrial fibrillation;
      - e. Arterial dissection.
    4. None of the following contraindications:
      - a. Intra-cardiac mass, vegetation, tumor or thrombus at the intended site of implant, or documented evidence of venous thrombus in the vessels through which access to the PFO is gained;
      - b. Vasculature through which access to the PFO is gained is inadequate to accommodate the appropriate sheath size;
      - c. Anatomy in which the Amplatzer PFO device size required would interfere with other intracardiac or intravascular structures, such as valves or pulmonary veins;
      - d. Other source of right-to-left shunts, including an atrial septal defect and/or fenestrated septum;
      - e. Active endocarditis or other untreated infections.
- II. It is the policy of health plans affiliated with Centene Corporation® that the percutaneous transcatheter closure of PFO is **experimental/investigational** for the following:
  - A. Devices not currently FDA-approved for PFO, including any of the following:
    1. CardioSEAL STARFlex Septal Closure System;

## CLINICAL POLICY

### Transcatheter Closure of Patent Foramen Ovale

2. Buttoned Device;
  3. Atrial Septal Defect Occluding System;
- B. Migraine prophylaxis;  
C. Primary stroke prevention;  
D. Unexplained oxygen desaturation.

#### Background

The foramen ovale is a particular structure of the fetal circulation that fails to close and is present in 25% of the adult population, forming a PFO.<sup>1,2</sup> The biological significance of PFOs have been widely debated in the literature for the last decade. Case control studies have established an association between an increased risk of ischemic stroke and the PFO.<sup>1</sup> Three initial randomized controlled trials (*e.g.* the CLOSURE I study, the PC study, and the RESPECT study), as well as a meta-analysis of 14 trials, collectively demonstrate that there is no significant advantage for surgical PFO closure to improve ischemic stroke prevention over medical therapy.<sup>7-10</sup>

However, four more recently published articles in *The New England Journal of Medicine* expand the body of work and extend analyses.<sup>2-6</sup> Mas *et al.* for the CLOSE investigators assessed 663 patients and demonstrated reduced recurrent stroke rates after PFO closure compared to oral anticoagulation with antiplatelet medical therapy in patients with cryptogenic stroke.<sup>2</sup> This finding was also validated by Søndergaard for the Gore REDUCE investigators in their analysis of 664 patients.<sup>4</sup> Furthermore, Saver *et al.* for the RESPECT investigators recapitulate earlier results in a multicenter trial, noting that closure of PFO was associated with a lower rate of recurrent ischemic stroke, after having followed 980 patients for a median of 5.9 years.<sup>3</sup> A meta-analysis of 6 RCTS demonstrated benefits of PFO closure for secondary prevention of stroke among patients with cryptogenic stroke and small increase in risk of new onset atrial fibrillation.<sup>24</sup>

The 2014 American Heart Association / American Stroke Association have not yet been updated to include recent randomized controlled trials (RCTs).<sup>11</sup> The American Heart Association published a 2018 review that stated that recent RCTs have demonstrated the superiority of PFO closure over pharmacological treatment in reducing risk of recurrent ischemic stroke in certain patients, and that governing societies should rewrite their guidelines accordingly.<sup>15</sup>

The American Academy of Neurology Practice advisory update summary on patent foramen ovale and secondary stroke prevention include the following recommendations:

- In patients being considered for PFO closure, clinicians should ensure that an appropriately thorough evaluation has been performed to rule out alternative mechanisms of stroke (level B).
- In patients with a higher risk alternative mechanism of stroke identified, clinicians should not routinely recommend PFO closure (level B).
- Clinicians should counsel patients that having a PFO is common; that it occurs in about 1 in 4 adults in the general population; that it is difficult to determine with certainty whether their PFO caused their stroke; and that PFO closure probably reduces recurrent stroke risk in select patients (level B).
- In patients younger than 60 years with a PFO and embolic-appearing infarct and no other mechanism of stroke identified, clinicians may recommend closure following a

## CLINICAL POLICY

### Transcatheter Closure of Patent Foramen Ovale

discussion of potential benefits (absolute recurrent stroke risk reduction of 3.4% at 5 years) and risks (periprocedural complication rate of 3.9% and increased absolute rate of non-periprocedural atrial fibrillation of 0.33% per year) (level C).<sup>24</sup>

#### Coding Implications

This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2020, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

| CPT® Codes | Description   |
|------------|---|
| 93580      | Percutaneous transcatheter closure of congenital interatrial communication (ie, Fontan fenestration, atrial septal defect) with implant |

| HCPCS Codes | Description                                |
|-------------|--|
| C1817       | Septal defect implant system, intracardiac |

#### ICD-10-CM Diagnosis Codes that Support Coverage Criteria

| ICD-10-CM Code | Description          |
|----------------|----------------------|
| Q21.1          | Atrial septal defect |

| Reviews, Revisions, and Approvals  | Date  | Approval Date |
|--|-------|---------------|
| Policy developed   | 11/17 | 12/17         |
| Removed the phrase “to reduce the risk of ischemic stroke” from the medical necessity statement in II. Specified that the “stroke prevention” in section II is “primary stroke prevention.”  | 06/18 |               |
| Added “but not limited to” to criteria regarding absence of other risk factors for ischemic stroke. Added hypercoagulation, arterial dissection, and atrial fibrillation as conditions that must be ruled out. Added contraindications per instruction manual. Updated background. | 11/18 | 11/18         |
| Annual review. Added Gore Cardioform as an FDA-approved device appropriate for medically necessary closure of PFO. Reviewed by specialist.   | 11/19 | 11/19         |
| Background updated with no impact on clinical criteria. References reviewed and updated. Replaced “member” with “member/enrollee” in all instances.  | 11/20 | 11/20         |

**References**

1. Nakanishi, Koki, Minoru Yoshiyama, and Shunichi Homma. "Patent foramen ovale and cryptogenic stroke." *Trends in Cardiovascular Medicine* (2017).
2. Mas, Jean-Louis, et al. "Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke." *The New England Journal of Medicine* 377.1. Sep. 2017: 1011-1021.
3. Saver, Jeffrey L., et al. "Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke." *The New England Journal of Medicine* 377.11. Sep 2017: 1022-1032.
4. Søndergaard, Lars, et al. "Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke." *The New England Journal of Medicine* 377.11. Sep 2017: 1033-1042.
5. Farb, Andrew, Nicole G. Ibrahim, and Bram D. Zuckerman. "Patent Foramen Ovale after Cryptogenic Stroke—Assessing the Evidence for Closure." *The New England Journal of Medicine* 377.11. Sep 2017: 1006-1008.
6. Ropper, Allan H. "Tipping Point for Patent Foramen Ovale Closure." (2017): 1093-1095.
7. Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry S, MacDonald LA, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. *The New England Journal of Medicine* 2013; 368:1092–100.
8. Meier B, Kalesan B, Mattle HP, Khattab AA, Hildick-Smith D, Dudek D, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. *The New England Journal of Medicine* 2013; 368:1083–91.
9. Furlan AJ, Reisman M, Massaro J, Mauri L, Adams H, Albers GW, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. *The New England Journal of Medicine* 2012; 366: 991–9.
10. Wolfrum M, Froehlich GM, Knapp G, Casaubon LK, Di Nicolantonio JJ, Lansky AJ, et al. Stroke prevention by percutaneous closure of patent foramen ovale: a systematic review and meta-analysis. *Heart* 2014; 100:389–95.
11. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association / American Stroke Association. *Stroke* 2014 ;45:2160–236
12. Messé, Steven R., et al. "Practice advisory: Recurrent stroke with patent foramen ovale (update of practice parameter) Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology* 87.8 (2016): 815-821.
13. Smer A, Salih M, Mahfood Haddad T, et al. Meta-analysis of Randomized Controlled Trials on Patent Foramen Ovale Closure Versus Medical Therapy for Secondary Prevention of Cryptogenic Stroke. *Am J Cardiol.* 2018 Jun 1;121(11):1393-1399.
14. Kuijpers T, Spencer FA, Siemieniuk RAC, et al. Patent foramen ovale closure, antiplatelet therapy or anticoagulation therapy alone for management of cryptogenic stroke? A clinical practice guideline. *BMJ.* 2018; 362: k2515. Published online 2018 Jul 25.
15. Collado FMS, Poulin MF, Murphy JJ, Jneid H, Kavinsky CJ. Patent Foramen Ovale Closure for Stroke Prevention and Other Disorders. *J Am Heart Assoc.* 2018 Jun 17;7(12). pii: e007146.
16. Lee PH, Song JK, Kim JS, et al. Cryptogenic Stroke and High-Risk Patent Foramen Ovale: The DEFENSE-PFO Trial. *J Am Coll Cardiol.* 2018 May 22;71(20):2335-2342.
17. St. Jude Medical Corporation. Amplatzer PFO Occluder Instructions for Use. 2018. Available at <https://manuals.sjm.com/>

**CLINICAL POLICY****Transcatheter Closure of Patent Foramen Ovale**

18. Abbott. Amplatzer PFO Occluder. Abbott. Accessed November 8, 2019.  
<https://www.cardiovascular.abbott/us/en/hcp/products/structural-heart/amplatzer-pfo.html>.
19. Hayes. Comparative Effectiveness Review of Transcatheter Closure of Patent Foramen Ovale for Prevention of Recurrent Cryptogenic Stroke. Medical Technology Directory. May 31, 2018. Update September 16, 2020. Accessed 11/3/20.
20. Messe, SR, Brecker, SJD. Treatment of patent foramen ovale (PFO) for secondary stroke prevention. UpToDate. Kasner SE, Connolly HM (Eds) UpToDate, Waltham, MA. Accessed 11/3/20.
21. Hayes Health Technology Assessment: Gore Cardioform Septal Occluder (W. L. Gore & Associates Inc.) for Closure of Atrial Septal Defects. Nov 30, 2017. Annual Review Dec 12, 2019. Accessed 11/2/20.
22. W.L. Gore & Associates Inc. Cardioform Septal Occluder Instructions for Use. Flagstaff, AZ. March 2018. <https://www.goremedical.com/products/cardioform/septal-occluder>
23. Nasir UB, Qureshi WT, Jogu H et al. Updated meta-analysis of closure of patent foramen ovale versus medical therapy after cryptogenic stroke. Cardiovasc Revasc Med. 2019 Mar;20(3):187-193. doi: 10.1016/j.carrev.2018.06.001. Epub 2018 Jun 13.
24. Messe SR, Gronseth GS, Kent DM, et al. Practice advisory update summary: Patent foramen ovale and secondary stroke prevention Report of the Guideline Subcommittee of the American Academy of Neurology. Neurology. 2020 May 19;94(20):876-885. doi: 10.1212/WNL.0000000000009443. Epub 2020 Apr 29. Accessed 11/3/20:  
<https://n.neurology.org/content/neurology/94/20/876.full.pdf>

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a

## CLINICAL POLICY

### Transcatheter Closure of Patent Foramen Ovale

discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of member/enrollees. This clinical policy is not intended to recommend treatment for member/enrollees. Member/enrollees should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, member/enrollees and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, member/enrollees and their representatives agree to be bound by such terms and conditions by providing services to member/enrollees and/or submitting claims for payment for such services.

**Note: For Medicaid member/enrollees**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

**Note: For Medicare member/enrollees**, to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs, LCDs, and Medicare Coverage Articles should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website at <http://www.cms.gov> for additional information.

©2017 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.